NCT04871594View on ClinicalTrials.gov

Pre-operative Immunotherapy in Stage II-III Urothelial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

June 2, 2023

Study Completion Date

December 30, 2024

Conditions
Urothelial Carcinoma
Interventions
DRUG

Nivolumab

On day 1, 22, and 43 240mg

Trial Locations (2)

1066 CX

Antoni van Leeuwenhoek ziekenhuis, Amsterdam

6525 GA

Radboud Universitair Medisch Centrum, Nijmegen

All Listed Sponsors
collaborator

4SC AG

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT04871594 - Pre-operative Immunotherapy in Stage II-III Urothelial Cancer | Biotech Hunter | Biotech Hunter